Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

20P - Tissue agnostic application of mTOR inhibitors for the management of therapy refractory solid tumors

Date

06 Oct 2021

Session

e-Posters

Presenters

Hossein Taghizadeh

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

H. Taghizadeh1, R. Mader2, G. Prager2, L. Müllauer3

Author affiliations

  • 1 Medical University of Vienna, Vienna/AT
  • 2 Medical University of Vienna, 1090 - Vienna/AT
  • 3 Medical University Vienna, 1090 - Vienna/AT
More

Abstract 20P

Background

In this analysis, we examined the efficacy, feasibility and limitations of the application of mTOR inhibitors based on the individual molecular profile of heavily pretreated cancer patients after failure of all standard treatments.

Methods

In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular characteristics of 70 cancer patients. Tumor samples of the patients were analyzed using next-generation sequencing panels of mutation hotspots, MSI testing, and immunohistochemistry. All profiles were reviewed by a multidisciplinary team to provide a targeted treatment recommendation after consensus discussion.

Results

Seventy cancer patients with activation of the p-mTOR pathway were offered a mTOR inhibitor-based targeted therapy and 17 (24%) of them eventually received the targeted therapy. Four patients (6%) achieved stable disease. The other 13 patients (19%) experienced progressive disease. The median time to treatment failure was 3.2 months. In total, we detected 133 mutations in 60 patients. The five most frequent mutations were TP53, PTEN, KRAS, ATR, and POLE that accounted for over 40% (46%) of all mutations.

Conclusions

The antitumoral activity of mTOR inhibitor in therapy-refractory solid tumors was modest.

Legal entity responsible for the study

G. Prager.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings